GenFleet Therapeutics (Shanghai) Inc. (02595.HK)

Genfleet Therapeutics (Shanghai), Inc. operates as a commercial-stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai and currently employs 94 full-time employees. The company went IPO on 2025-09-19. The firm provides effective new treatment solutions for tumors, autoimmune and inflammatory diseases, covering target discovery, molecular discovery and evaluation, translational science and clinical development, as well as key chemistry manufacturing and controls aspects including formulation research, process development and quality analysis. The firm is mainly engaged in the development of new molecular entities, novel molecular modalities, investigation of molecular process routes and quality standards, and exploration of differentiated clinical development strategies and paths. The firm mainly primarily operates in the domestic and international markets.